Free subscription to the Capitol Journal keeps you current on legislative and regulatory news.
States Continue to Target AI-Driven Rental Pricing Nineteen states are considering bills that would limit the use of third-party software relying on competitor data to set rental housing prices, according...
Trump, Congress Weigh Measures to Preempt State AI Laws The Trump administration circulated—and then put on hold—a draft executive order aimed at preempting state laws regulating artificial...
Last year, after Colorado and California became the first states in the nation to expand privacy protections to include neural data, we said more states could follow suit . This year two more have done...
MI Lawmakers Advance Medical Debt Protections The Michigan Senate’s Health Policy Committee has advanced a trio of bipartisan bills aimed at reducing the burden of medical costs on residents of...
EU Reversing Course on Tech Regulation After aggressively regulating the technology industry for over a decade, the European Union is moving to loosen its landmark digital privacy and artificial intelligence...
* The views expressed in externally authored materials linked or published on this site do not necessarily reflect the views of LexisNexis Legal & Professional.
With popular weight-loss drugs like Mounjaro, Ozempic and Wegovy in short supply, many doctors, pharmacies and other providers have begun offering compounded versions of the drugs tailored to the needs of individual patients. They’re allowed to do so because the active ingredients in the drugs—semaglutide or tirzepatide—are listed on the U.S. Food and Drug Administration’s drug shortage list.
While commercial drugs are regulated by the FDA, states are responsible for the licensing and oversight of compounding pharmacies, and they’re now struggling to stay on top of that job. Idaho and Tennessee recently announced investigations of medical spas and other providers that may have been dispensing compounded weight-loss drugs illegally. And California and other states are considering strengthening their oversight of providers that offer such drugs. (NATIONAL CONFERENCE OF STATE LEGISLATURES)
Vermont Attorney General Charity Clark (D) filed a lawsuit against pharmacy benefit managers Express Scripts and CVS Caremark, accusing them of squeezing out competition and driving up prescription drug costs. The suit claims the two PBMs control more than 95% of Vermont’s pharmacy benefit market, giving them the power to dictate which drugs are covered by insurers. (LAW360)
AstraZeneca and AbbVie have filed lawsuits challenging legislation enacted in Kansas in April (SB 28) preventing drug companies from limiting the ability of pharmacies under contract with eligible hospitals and clinics to obtain outpatient prescription drugs at discounted prices, as provided for by the federal 340B drug discount program. The drug makers claim the federal program wasn’t intended to cover pharmacy chains like CVS and Walgreens. (KANSAS REFLECTOR)
—Compiled by SNCJ Managing Editor KOREY CLARK
Visit our webpage to connect with a LexisNexis® State Net® representative and learn how the State Net legislative and regulatory tracking service can help you identify, track, analyze and report on relevant legislative and regulatory developments.